CClinicalTrials.gg
CompletedNCT05665634Updated Jan 22, 2024

Concurrent TMS and EEG Pilot Study

An interventional study of Concurrent transcranial magnetic stimulation and electroencephalogram in Healthy, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will investigate the test-retest reliability of transcranial magnetic stimulation (TMS) -evoked potentials (TEPs) as measured by electroencephalography (EEG), using three different TMS protocols over five different brain regions in healthy volunteers. The goal is to compare the test-retest reliability of single pulse, inhibitory and excitatory TMS protocols as well as two distinct targeting approaches. The main questions to answer are:

  1. This study will investigate whether the test-retest reliability of TEPs differ across TMS protocols.
  2. This study will investigate whether the test-retest reliability of TEPs differ between individualized and non-individualized targeting approaches.
Read the detailed description

Participants will first undergo functional magnetic resonance imaging (fMRI) scanning where structural and resting-state functional images will be obtained. In two separate sessions, participants will attend two concurrent TMS/EEG session with one week in between.

During the TMS/EEG sessions, an EEG cap will be placed on the participant's head and the resting motor threshold will be obtained to calibrate the TMS intensity required for the stimulation of target regions. Once setup procedures are complete, eleven total blocks of TMS with simultaneous EEG recording will take place. Among eleven blocks, five of will use single-pulse stimulation (to stimulate cortical excitation), three will use paired-pulse stimulation with 3ms between pulses (to stimulate cortical inhibition), and three will use paired-pulse stimulation with 11ms between pulses (to stimulate greater cortical excitation). Five different brain regions will be targeted: three individualized targets either derived anatomically (motor cortex) or based on the individual's resting-state functional connectivity (dorsolateral prefrontal cortex and angular gryus) and two regions that are based on the literature (dorsolateral prefrontal cortex and angular gryus).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.

Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Medically and psychiatrically healthy
  • Between the ages of 18 and 65 years old
  • Fluent in English and capable of providing informed consent
  • Willing to remove any jewelry, hair clips, bobby pins, or any other potentially conducting or magnetic objects worn on or near the head

Exclusion criteria

Exclusion Criteria:

  • Weight greater than 350 lbs (the weight limit of the specialized TMS/EEG chair)
  • Current serious medical or psychiatric illness, or recent heart disease
  • Acute intoxication with any drug of abuse, including alcohol or cannabis
  • Pregnancy
  • History of neurological problems, including epilepsy, seizures, syncope, tinnitus, migraine, or frequent non-migraine (e.g. tension) headaches
  • History of head trauma associated with loss of consciousness
  • Language or hearing impairment that would undermine communication regarding consent, study procedures, and overall volunteer safety.
  • Irritable skin
  • For those undergoing MRI procedures in the current study: Any standard MRI contraindication (including implanted medical devices, metal in the body, or claustrophobia incompatible with MRI procedures)
  • TMS-contraindicated medical devices, including cochlear implants, pacemaker, neurosensory stimulator, implantable defibrillator, insulin pump, clips, stents, or shunts that may be disrupted by or interact with TMS coil operation
  • Taking medications that lower seizure threshold (see Appendix A: List of Contraindicated Medications)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    All participants

    Device: Concurrent transcranial magnetic stimulation and electroencephalogram

Interventions

  • DeviceConcurrent transcranial magnetic stimulation and electroencephalogram

    Single and paired-pulse TMS will be applied to 5 different brain regions during simultaneous recording of EEG. Paired-pulse stimulations will have either 3 ms or 11 ms between pulses, to stimulate cortical inhibition and excitation respectively. Stimulation intensity for single-pulse stimulation blocks will be 120% of the resting motor threshold (RMT). For paired-pulse blocks, the conditioning (first) pulse will be delivered at a stimulation intensity of 80% RMT, and the test (second) pulse will be delivered at 120% RMT. Each test block will consist of 60 TMS trials and will last for 5 minutes. Order of test blocks will be pseudo-randomized across participants. Out of 5 stimulation sites, 3 will be determined based on individual's own brain anatomy and resting state connectivity. These 3 regions will be stimulated using all 3 TMS protocols. The other two regions will be determined based on the literature and only be targeted using the single pulse TMS protocol.

06

What researchers measure

Primary outcomes

  1. Comparison of interclass correlation coefficients (ICC) of TMS Evoked Potential amplitudes, as measured by EEG, between single and paired-pulse TMS protocols

    TMS evoked potentials (TEP) during single and paired-pulse protocols will be measured by simultaneous EEG recording. TEP amplitudes at approximately 40, 60, 100 and 200 ms will be calculated per subject, individualized brain region (anatomically based M1, connectivity based DLPFC and angular gyrus), TMS protocol and session. ICCs will be calculated across sessions and subjects per TEP for each individualized brain region and TMS protocol. ICCs per brain region will be compared between single and paired-pulse TMS protocols.

    Time frame: Session 1 and session 2 with one week between sessions

  2. Comparison of interclass correlation coefficients (ICC) of TMS Evoked Potential amplitudes, as measured by EEG, between individualized and non-individualized targeting approaches

    TMS evoked potentials (TEP) during single pulse TMS protocols will be measured by simultaneous EEG recording. TEP amplitudes at approximately 40, 60, 100 and 200 ms will be calculated per subject, individualized and non-individualized (connectivity-based vs literature-based DLPFC and angular gyrus) brain region and session. ICCs will be calculated across sessions and subjects per TEP for all brain regions (connectivity-based vs literature-based DLPFC and angular gyrus) that were targeted by single-pulse protocols. ICCs will be compared between individualized and non-individualized targeting approaches.

    Time frame: Session 1 and session 2 with one week between sessions

07

Study locations

1 site
  • Johns Hopkins Medicine
    Baltimore, Maryland 21211, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05665634
Lead sponsor
Johns Hopkins University
Responsible party
Sponsor
First posted
Dec 27, 2022
Start date
Dec 2, 2022
Primary completion
Nov 20, 2023
Completion
Nov 20, 2023
Last update
Jan 22, 2024

Study contacts

Fred Barrett
principal investigator · Johns Hopkins University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion